Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2016

View Archived Issues

Aurigene announces the exercise of Curis' option for CA-327

WK-0202 shows protective effects against Adriamycin-induced cardiotoxicity

Daiichi Sankyo and Dana-Farber Cancer Institute enter preclinical research collaboration

Ablynx discloses second extension of collaboration with Merck & Co. subsidiary

Transgene enters collaboration with Merck KGaA and Pfizer

First-line ribociclib plus letrozole highly effective in phase III breast cancer trial

Immunovaccine reports results from phase I trial of DPX-RSV

ContraVir reports interim data from phase IIa trial of CMX-157 in HBV

Aptose receives response from FDA regarding clinical hold for phase Ib trial of APTO-253

NIH grants support to Recombinetics' development of swine models of Alzheimer's and NF2

TG Therapeutics files amended protocol with FDA for GENUINE phase III trial

Regeneron and Ocular Therapeutix to develop sustained-release aflibercept for ophthalmic indications

Shenyang Sunshine Pharmaceutical patents PHD2 inhibitors

Sichuan Kelun Pharmaceutical Research discloses anticancer agents

SIWA-318 inhibits tumor metastasis in breast cancer mouse model

ZMapp beneficial but not superior to standard care in PREVAIL II Ebola virus disease trial

McGill University and Florida Institute of Technology describe OXER1 antagonists

Human Stem Cells Institute licenses Neovasculgen to ArtGen for development in the U.S. and Canada

Vertex Pharmaceuticals develops PAR2 antagonists

Anvyl presents deuterated etifoxine analogs

Sunovion submits NDA for SUN-101/Eflow

Novel mutation in GRK1 gene may cause Oguchi disease

Limited activity seen with single-agent buparlisib treatment in CNS lymphoma trial

Aslan enters collaboration with Nanyang Technological University to develop modybodies

Oncogenex Pharmaceuticals reports results for phase III ENSPIRIT trial of custirsen

Novel KERA mutations associated with cornea plana

AC-0010 shows promising anticancer activity in NSCLC patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...